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Following publication of the original article \[1\], the authors reported errors in Fig. [3](#Fig1){ref-type="fig"}, Fig. [14](#Fig2){ref-type="fig"}a, Fig. [18](#Fig3){ref-type="fig"}, Fig. [19](#Fig4){ref-type="fig"}b, Additional file [3](#MOESM1){ref-type="media"} and Additional file [7](#MOESM2){ref-type="media"}. The title of Additional file [9](#MOESM3){ref-type="media"} contains a typing error and is correctly given below. Fig. 3Most active compound (IC~50~ = 0.2) mapped to all the features Fig. 14a Molecular interaction between the reference- protein (purple). Green dotted lines indicate the hydrogen bonds. The residues are represented in orange stick model Fig. 18Binding mode assessment of compounds. The co-crystal is represented in gray, reference is denoted in green and the Hit in orange. All the three follow the same pattern Fig. 19b Intermolecular interactions between the ligand and the protein. Green dotted lines represent the hydrogen bonds. The protein residues are indicated in cyan

The following typing errors have been identified: Page noColumn/paragraphlinePresent wordChange to1Abstract/results2ofabove21/22CyclicCyclin22/13VEGFRVEGFR-2122/13prognosisprogression122/110formfrom19Above conclusions4Cyc919Cys919102/11320 ps20 ns102/11525 ps25 ns132/16fourfiveTable 5/ referencevan der Waals interactions--asn900leu1044Asn900, Ile1044Fig 10----30 ps30 nsFig 16----refrencereference

Further to this, in Table [1](#Tab1){ref-type="table"}, HyP is incorrectly represented as HyB and Hy-Ali as HyAli/HY-Ali. The corrected Table [1](#Tab1){ref-type="table"} can be found here. Table 1Hypo noTotal cost^a^Cost differenceRMSD^b^CorrelationFeatures^c^Max fitHypo1111.9571.220.70.97Hy-Ali, 2HyP,RA11.4Hypo 2113.3169.860.70.96Hy-Ali, 2HyP,RA11.5Hypo 3116.4566.710.80.95Hy-Ali,HyP,RA,HBA11.9Hypo 4116.4766.691.00.94HBA, HBD 2HyP10.7Hypo 5117.1166.050.90.94Hy-Ali,HyP,RA,HBA11.5Hypo 6119.5163.651.00.93HBA,HBD,2HyP11.26Hypo 7119.5263.650.90.95HBA,2HyP,RA12.65Hypo 8119.8263.350.90.94HBA,Hy-Ali,HBD,RA12.33Hypo 9119.9463.231.20.91HBA,Hy-Ali,2HyP, RA11.98Hypo10120.5262.651.10.91HBA,HBD, Hy-Ali7.8

These corrections do not alter the context of the manuscript.
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**Additional file 3.** 2D interaction representation of the reference compound and 4AG8. Detailed molecular interactions of the reference compound. **Additional file 7.** 2D interaction representation of the reference compound and 1URW. Molecular interaction details of the reference compound. **Additional file 9.** Active sites comparison. Comparison of the active site residues of 4AG8 and 1URW.
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